1. Web alert

   News Pages: 393 - 394

2. Clinical trials report

   • Heinrich Taegtmeyer

   BriefCommunication Pages: 397 - 398

3. Clinical trials report

   • Mark A. Kudes
   • John D. Bisognano

   BriefCommunication Pages: 399 - 400

4. Heart and liver fatty acid binding proteins and the metabolic syndrome

   • Bert Binas

   OriginalPaper Pages: 401 - 406

5. Malonyl-CoA decarboxylase is a major regulator of myocardial fatty acid oxidation

   • Karalyn D. Cuthbert
   • Jason R. B. Dyck

   OriginalPaper Pages: 407 - 411

6. Lipotoxicity in the heart

   • Nica M. Borradaile
   • Jean E. Schaffer

   OriginalPaper Pages: 412 - 417

7. Role of hypertension in the metabolic syndrome: Who is affected?

   • Gladys Velarde
   • Bradford C. Berk

   OriginalPaper Pages: 418 - 426

8. You are what you breathe: Evidence linking air pollution and blood pressure

   • Robert D. Brook

   OriginalPaper Pages: 427 - 434

9. Clinical trials report

   • George Mansour
   • Janette Mansour

   BriefCommunication Pages: 437 - 438

10. Management of hypertension and diabetes: Treatment goals, drug choices, current practice, and strategies for improving care

    • Ann M. Borzecki
    • Dan R. Berlowitz

    OriginalPaper Pages: 439 - 449

11. Hypertension and head injury

    • Tadahiko Shiozaki

    OriginalPaper Pages: 450 - 453

12. Hypertension in young children and neonates

    • John Edward Jones
    • Pedro A. Jose

    OriginalPaper Pages: 454 - 460

13. Selection of antihypertensive agents in patients at risk for diabetes

    • Susan Simmons Holcomb

    OriginalPaper Pages: 461 - 465

14. Antihypertensive agents for aging patients who are at risk for cognitive dysfunction

    • Ihab Hajjar
    • Michelle Keown
    • Brandy Frost

    OriginalPaper Pages: 466 - 473

15. Does ALLHAT change the management of hypertension in chronic kidney disease?

    • Martin MacKinnon
    • Frans H. H. Leenen
    • Marcel Ruzicka

    OriginalPaper Pages: 474 - 483